No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MURA Mural Oncology
- 3.230
- -0.070-2.12%
Close Jun 18 16:00 ET
- 3.250
- +0.020+0.62%
Post 17:40 ET
54.66MMarket Cap-284P/E (TTM)
3.320High3.190Low103.86KVolume3.290Open3.300Pre Close336.37KTurnover0.68%Turnover RatioLossP/E (Static)16.92MShares57.20052wk High0.23P/B49.30MFloat Cap3.13052wk Low--Dividend TTM15.26MShs Float57.200Historical High--Div YieldTTM3.94%Amplitude3.130Historical Low3.238Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
Express News | Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Mural Oncology Presents Clinical Data From ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural's late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally
Mural Oncology | 10-Q: Quarterly report
Express News | Mural Oncology PLC Qtrly Shr Loss $1.84
Mural Oncology 1Q Research and Development Expenses $26.9M >MURA
Mural Oncology 1Q Research and Development Expenses $26.9M >MURA
Comments
$Mural Oncology(MURA.US$
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...
1
$Mural Oncology(MURA.US$
NEWS
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
NEWS
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
$Mural Oncology(MURA.US$ how do you circuit-break on 30cents,.
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg